Mark Dysinger

Alexion Pharmaceuticals

Rare disease: How miniaturized immunoassays are advancing therapeutic development

Developing therapeutics for rare diseases often means working with small sample numbers. In this interview, Mark Dysinger, Developmental Scientist III, Bioanalytical Development, Alexion Pharmaceuticals, describes how miniaturized immunoassays enable accurate analysis of drug-target engagement. Hear how Gyros Protein Technologies’ Gyrolab® novel immunoassay technology overcomes the challenges of traditional ligand-binding assays used in the analysis of pharmacokinetics, pharmacodynamics and anti-drug antibodies, is suitable for regulated work, and how these assays can be easily transferred to partner laboratories.



LIKE 1


Mark Dysinger
Biotherapeutics Drug Discovery

Mark Dysinger

Biography

Mark Dysinger is a development scientist in the bioanalytical development at Alexion Pharmaceuticals in New Haven, Connecticut. More
Follow Mark

Mark Dysinger

Alexion Pharmaceuticals

Mark Dysinger is a development scientist in the bioanalytical development at Alexion Pharmaceuticals in New Haven, Connecticut. In this role, he is a bioanalytical project representative for novel rare disease drug therapies and is heavily involved in method development, assay validation, and sample analysis for both preclinical and clinical trials. Mark has over 20 years’ experience in the pharmaceutical industry and holds a Master of Science degree in biotechnology from the University of Maryland University College and a bachelor’s degree in zoology from the University of Maine.